Bayforest Capital Ltd Invests $344,000 in Progyny, Inc. $PGNY

Bayforest Capital Ltd acquired a new position in shares of Progyny, Inc. (NASDAQ:PGNY) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 15,392 shares of the company’s stock, valued at approximately $344,000.

A number of other large investors also recently modified their holdings of the business. New York State Teachers Retirement System boosted its stake in shares of Progyny by 0.7% during the 1st quarter. New York State Teachers Retirement System now owns 73,200 shares of the company’s stock worth $1,635,000 after buying an additional 500 shares during the last quarter. Polen Capital Management LLC lifted its stake in Progyny by 0.3% in the 1st quarter. Polen Capital Management LLC now owns 261,506 shares of the company’s stock valued at $5,842,000 after purchasing an additional 798 shares during the last quarter. Invesco Ltd. lifted its stake in Progyny by 0.4% in the 1st quarter. Invesco Ltd. now owns 275,936 shares of the company’s stock valued at $6,164,000 after purchasing an additional 1,117 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Progyny in the 1st quarter valued at about $44,000. Finally, AlphaQuest LLC lifted its stake in Progyny by 57.9% in the 1st quarter. AlphaQuest LLC now owns 5,668 shares of the company’s stock valued at $127,000 after purchasing an additional 2,079 shares during the last quarter. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Stock Down 1.5%

Progyny stock opened at $22.63 on Thursday. The stock has a market cap of $1.95 billion, a P/E ratio of 38.36, a P/E/G ratio of 1.88 and a beta of 1.33. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $26.76. The company’s 50-day moving average price is $23.00 and its two-hundred day moving average price is $22.22.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.19 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.23). The company had revenue of $332.87 million during the quarter, compared to the consensus estimate of $315.70 million. Progyny had a net margin of 4.28% and a return on equity of 10.69%. The firm’s revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.17 earnings per share. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. Equities analysts anticipate that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Leerink Partnrs upgraded shares of Progyny from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 8th. Leerink Partners upgraded shares of Progyny from a “market perform” rating to an “outperform” rating and set a $28.00 target price for the company in a research note on Tuesday, July 8th. Wall Street Zen upgraded shares of Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Raymond James Financial set a $28.00 target price on shares of Progyny in a research note on Friday, August 8th. Finally, Truist Financial raised their target price on shares of Progyny from $24.00 to $27.00 and gave the company a “hold” rating in a research note on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $25.30.

Insider Activity at Progyny

In other news, EVP Allison Swartz sold 2,398 shares of the firm’s stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $22.96, for a total transaction of $55,058.08. Following the transaction, the executive vice president directly owned 79,697 shares of the company’s stock, valued at approximately $1,829,843.12. This trade represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kevin K. Gordon sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $22.04, for a total transaction of $55,100.00. Following the transaction, the director directly owned 12,501 shares in the company, valued at $275,522.04. This represents a 16.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 7,895 shares of company stock worth $179,311 over the last ninety days. Insiders own 9.40% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.